Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
European Journal of Neurology|September 5, 2024
Patient-reported daily functioning after SARS-CoV-2 vaccinations in autoimmune neuromuscular diseasesKoos P J van Dam, Luuk Wieske, Eileen W Stalman, et al.
Journal of Neuroimmunology|October 14, 2022
Enrichment of serum IgG4 in MuSK myasthenia gravis patientsDana L E Vergoossen, Annabel M Ruiter, Kevin R Keene, et al.
BMC Medicine|March 3, 2022
Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseasesLuuk Wieske, Laura Y L Kummer, Koos P J van Dam, et al.
Journal of Autoimmunity|January 9, 2023
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinationsKoos P J van Dam, Luuk Wieske, Eileen W Stalman, et al.
BMC Infectious Diseases|May 17, 2023
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activityKoos P J van Dam, Adriaan G Volkers, Luuk Wieske, et al.
The Journal of Dermatology|February 14, 2025
Impact of COVID-19 disease and vaccination on dermatological immune-mediated inflammatory diseases atopic dermatitis, psoriasis, and vitiligo: a Target2B! substudyNicoline F van Buchem-Post, Wouter Ouwerkerk, Eileen W Stalman, et al.
Annals of the Rheumatic Diseases|November 10, 2022
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseasesEileen W Stalman, Luuk Wieske, Koos P J van Dam, et al.
The Lancet. Rheumatology|March 23, 2022
Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort studyLuuk Wieske, Koos P J van Dam, Maurice Steenhuis, et al.
The Journal of Allergy and Clinical Immunology|May 19, 2024
Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapyEileen W Stalman, Luuk Wieske, Jim B D Keijser, et al.
The Lancet. Rheumatology|May 9, 2022
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studiesLaura Boekel, Eileen W Stalman, Luuk Wieske, et al.
Pageof 4